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Abstract: Benzalkonium chloride (BAK) is a cationic detergent with a very slow turnover. Because of its strong
antibacterial activities, BAK is widely used especially in dentistry and ophthalmology. It is the most commonly
used preservative in topical ophthalmic medications. Due to chronicity and widespread use of such treatments,
BAK’s side effects are of great importance. BAK toxicity for adherent cells, probably related to its pro-oxidative
activities, is time- and dose-dependent. Although lymphocytes often infiltrate superficial eye tissues, the BAK
influence on them is yet to be established. The aim of this study was to check BAK cytotoxicity on T lymphocytic
Jurkat line cells and to verify the suggestion that BAK can induce G2M cell blocks. A dose- and time-dependent
cytotoxic effect of BAK on lymphoid cells in relatively low concentrations was shown in this study. In lower
concentrations, it shows a moderate apoptotic and minimal antiproliferative effect on Jurkat cells, while in
higher concentrations it shows a rapid necrotic effect. No G2M cell blocks were observed. Our findings could
suggest lymphoid dysfunction during intensive, prolonged topical BAK treatment, even at dosages relatively
non-toxic to epithelial eye cells. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 2, pp. 225–230)
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Introduction
Benzalkonium chloride (BAK) is a cationic detergent
expressing a high affinity to membrane proteins. It
changes the ionic resistance of the cell membranes
[1]. BAK, due to its antibacterial activities, is widely
used especially in ophthalmology and dentistry. Its
concentration in oral disinfectant mouthwash can
reach as much as 10% [2] whereas in eye drops it var-
ies between 0.004–0.05% [3]. Due to chronicity and
widespread use of such treatments, BAK’s side ef-
fects are of great importance. BAK’s toxicity, proba-
bly related to its pro-oxidative activities [2], is time-
and dose-dependent. It also causes protein denatur-
ation and disruption of the cytoplasmatic membranes
[1]. This phenomenon could be helpful in increasing
the penetrative abilities of the ophthalmologic solu-
tion’s active compounds [4, 5]. Moreover, some of the
active ophthalmological compounds e.g. prostaglan-
dins exert a protective effect against the cytotoxicity
of BAK [1, 6–8]. BAK can also decrease expression
of MUC5AC on conjunctival cells, causing mucin de-
ficiency and dry eyes in patients undergoing prolonged
topical ophthalmic therapy [1, 6] and influence the
generation of inflammation. Conjunctival expression
of intercellular adhesion molecule-1 (ICAM-1,
CD54), platelet-endothelial cell adhesion molecule-1
(PECAM-1, CD31) and HLA-DR could be increased
after their contact with BAK attracting and activat-
ing lymphocytes [1, 7].
In our recent publication, we showed that eight
different commercially available anti-glaucoma topi-
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cal medications induce cell necrosis or apoptosis and
suppress proliferation of human corneal line cells in
a dose- and time-dependent manner. Moreover, some
of them cause G2M cell blocks. All these ophthalmo-
logic drops contain BAK as a preservative [9]. The
aim of this paper was to establish the role of BAK in
these observed phenomena.
Material and methods
Cell culture. A Jurkat cell line purchased from American
Tissue and Cell Collection (Rockville, MD, USA) was used
in all experiments. Jurkat is a pseudodiploid human cell line
originated from acute T-cell leukemia. Cells were cultured
at 37oC in a humidified atmosphere with the addition of 5%
CO2 in air in RPMI 1640 (Biochrom AG, Berlin, Germany)
supplemented with 10% newborn calf serum (Gibco, Pais-
ley, UK), 100 U/ml penicillin (Sigma, Poznan, Poland), 200
μg/ml neomycin (Sigma) and 100 μg/ml streptomycin (Sig-
ma). The cultures were periodically checked for Mycoplas-
ma infections. In order to maintain asynchronous, exponen-
tial growth, cultures were splitted daily by 1:1 dilution.
BAK experiments. Benzalkonium chloride (BAK) was
purchased from Sigma. 5% (~140 mM) stock solution of
BAK was prepared in distilled water and stored in a refrig-
erator for a couple of days. BAK stock solution was admin-
istered directly into the culture flasks to obtain the final
concentration, as indicated in the text and in the figure
captions. BAK’s influence on cells was checked in the
range between 0.000001–0.5% (28 nM–14 mM). In key
concentrations, experiments were performed in at least
five repetitions.
Viability experiments. Propidium iodide (PI) (Sigma) was
added to the cell suspension collected directly from the cul-
ture flask at a final concentration of 1 μg/ml. After a short
incubation, the cells were analyzed in a flow cytometer
(FACSCalibur, BD Biosciences) equipped with a 488 nm laser.
Specific PI fluorescence was measured as FL3. FCS low/PI+ cells
were considered as dead, and FCS high/PI– cells as live.
Cell cycle experiments. The cells, treated with different
concentrations of medications for various time intervals as
indicated in the ‘Results’ section, were stained with acridin
orange (AO) and subsequently analyzed by flow cytometry,
as described previously [10, 11]. Using acridin orange assay
enabled us to measure both RNA and DNA content in
a single cell. This is crucial, not only for cell cycle positioning,
but also to distinguish between apoptosis and necrosis
(Figure 1). At least 10,000 cells were analyzed [10–12].
Statistical analysis. GraphPad Prism software and Wilcox-
on matched paired tests were applied for statistical analysis
as well as for preparation of distribution diagrams.
Results
BAK’s dose- and time-dependent toxic effects were
investigated in this study. In BAK concentrations
higher than 0.0001%, Jurkat cells rapidly die show-
ing a necrotic mode of cell death (Figure 2). Using
BAK in the range between 0.00001–0.0001% (0.28–
–2.8 μM) slightly induces apoptosis in a dose- and time-
dependent mode (Figures 1, 3). Jurkat cell median
apoptosis after 48 hours of cultivation significantly
increased from 8.3% seen in control to 17% in
0.0001% (2.8 μM) BAK concentration. BAK does not
induce any type of cell death in concentrations lower
than 0.00001% (0.28 μM) (data not shown).
These results were confirmed by viability results.
BAK showed dose- and time-dependent effects on
the viability of Jurkat cells with almost no effect in
concentrations lower than 0.00001% (0.28 μM) (data
not shown) and a slight effect in the range between
0.00001–0.0001% (0.28–2.8 μM). Dramatic loss of
viability was observed in concentrations higher than
0.0001% (2.8 μM) (Figure 2).
No major cell cycle blocks as a result of BAK influ-
ence were seen in concentrations up to 0.0001%
(2.8 μM) (Figure 3). A slight but significant decrease of
cell numbers in S phase seen in cultures with addition
of 0.00003–0.0001% (1.4–2.8 μM) BAK, especially af-
ter 48 hours of cultivation, was observed. This phenom-
enon could be the result of BAK’s cytostatic effect (Fig-
ure 3). Due to rapid cell death, cell cycle analysis could
not be performed in higher BAK concentrations.
Discussion
Eye preservative turnover is very slow. The lipo-
philic nature of most of them causes them to bind
to the ocular tissues immediately after application
and prolongs their action for as long as hundreds
of hours. The half-time of BAK elimination from
the eye surface is approximately 20 hours [13, 14].
This is why we decided to use the long term culture
model in this study. We showed that BAK induces
necrosis (concentration > 0.0001%), apoptosis
(concentration 0.00001–0.0001%) or has no major
influence (concentration < 0.00001%) on Jurkat
line cells. The Jurkat cell line originates from T lym-
phocytes. Although lymphocytes do not infiltrate
the cornea in physiological conditions, they are
present in other parts of the anterior segment of
the eye as an anterior chamber or a conjunctiva in
both physiological and pathological conditions and
are a subject for BAK stimulation. Moreover, ex-
posure to BAK increases permability of eye tissues
[4, 5] and can have a proinflammatory effect. It in-
creases corneal epithelial cell expression of cell
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adhesion molecules helping lymphocytes to reach
the site of inflammation, and also expression of
HLA-DR, which is crucial for antigen presentation
needed for lymphocyte activation [1, 7]. This data
is supported by clinical observations showing an im-
munologic reaction with increased presence of lym-
phocytes, Langerhans cells and macrophages in pa-
tients subjected to chronic application of preserva-
tives. Moreover, sometimes such inflammations can
lead to subconjunctival fibrosis [15].
In our recent study, we showed that almost all ex-
amined commercially available anti-glaucoma medi-
cations decrease the number of corneal epithelial cells
during their cultivation due to induction cell death
and proliferation suppression [9]. This observation
can be explained not only by the effect of active sub-
stances, but also by BAK action. Many other in vitro
studies have shown that preservatives are cytotoxic,
especially for the cells of the ocular surface: conjunc-
tival and corneal epithelium and keratocytes [7, 9, 14,
16–19] but also for the deeper ocular tissues (fibro-
blast of Tenon’s capsule, cells of lens epithelium and
trabecular meshwork) [15, 20]. Although the cytotoxic
effect of BAK is well documented in patients [15] and
on cultivated adherent cells, its influence on lympho-
cytes seems not to have been explored until this study.
Lymphocytes seem to be very sensitive to the cyto-
toxic effect of BAK. Cytotoxic and proapoptotic
BAK concentrations for corneal and conjunctiva
cells are higher than seen in this study for lympho-
cytes, and vary between 0.0001 and 0.02%, but most
of them are close to the latter figure [5, 7, 8, 14, 17, 18].
Huge differences in these concentrations are prob-
ably due to differences in methods of cell treatments
by BAK (especially in treatment and recovery time)
and sensitivities of assays. Trabecular meshwork cells
also seem to be very sensitive to BAK stimulation:
in concentrations as low as 0.00015%, it kills about
20% of cells [20].
Our present data also shows minimal anti-prolif-
erative BAK effect on lymphoid cells. The number of
cells in S phase was slightly reduced in cultures (es-
pecially those lasting 48 hours) treated with a sub-
toxic dosage of BAC. This suggests that in clinical
conditions, the proliferation of lymphocytes is more
resistant for BAK suppressive influence than cells
Figure 1. After 48 hours’ cultivation of Jurkat cells in the absence or presence of benzalkonium chloride (BAK) at
different concentrations, cells were stained with acridine orange (AO) and subsequently analyzed in flow cytometry
(FACS Calibur, BD Biosciences). Usage of AO assay enabled us to measure both DNA and RNA cell contents. DNA
histograms are shown in upper row. Cell cycle distribution is also presented as dotplots in lower row. Please note that
necrotic cells show not only lower RNA, but also DNA content
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Figure 2. Jurkat cells were cultured in the absence or presence of different concentrations of benzalkonium chloride
(BAK) for 24 or 48 hours. To check their viability, cells were stained with PI (1 μg/ml) and subsequently analyzed in a flow
cytometer (FACSCalibur). In upper row, dotplots show cellular size (FSC) versus fluorescence of PI (each dot represents
a single cell) of Jurkat cells cultured for 24 hours. Dead cells were defined as FCS low/PI+ and live ones as FCS high/PI–.
Calculated numbers of live cells are presented in lower panel. Medians are marked as lines. Statistical analysis and graphs
were performed using GraphPad Prism software. Significant differences (p < 0.05) to the control are marked as *
Figure 3. Jurkat cells were cultured in the absence or presence of benzalkonium chloride (BAK) at different concentra-
tions for 24 or 48 hours, stained with acridine orange (AO) as described previously [10, 11] and subsequently analyzed via
flow cytometry (FACSCalibur). Cell cycle distributions were calculated and are presented as distribution diagrams.
Medians are marked as lines. Diagrams were prepared using GraphPad Prism software. Significant differences (p < 0.05)
to the control are marked as *
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originating from the eye. On the other hand, it should
be stated that this anti-proliferative lymphocytic dos-
age is still much lower than that for epithelial cells.
Sub-toxic BAK stimulation was also applied on pri-
mary human gingival fibroblasts. An IC50 dose of
BAK was unable to break down artificial G0/G1 block,
resulting in no S and G2M cell progression [2].
Pauly et al. reported that 0.01% BAK stimulation
of corneal epithelial cells tripled their proliferation
(measured as percentage of Ki-67+ cells) as a mecha-
nism of cell defense. On the other hand, lower BAK
concentrations do not alter the proliferative abilities
of cells, while higher concentrations (even 0.02%)
completely abolish proliferation [5]. Proliferation of
human corneal keratocytes has also been measured
by [3H] thymidine methodology. BAK at a concen-
tration of 0.01 mg/ml significantly decreases the pro-
liferation of such cells, whereas its lower concentra-
tion does not affect it [21]. It also should be stated
that BAK influences superficial cells, e.g. corneal
epithelial cells or conjunctival cells, in higher concen-
trations than on infiltrating lymphocytes, even includ-
ing BAK’s effect on increasing the permeability of
eye tissue.
Our findings in this study do not confirm the sug-
gestion that BAK can induce G2M block. Such blocks
were observed in some human corneal line cells treat-
ed with  commercial anti-glaucoma medication con-
taining BAK [9]. This observation has not been con-
firmed in vitro by others on corneal cells [18], prima-
ry gingival fibroblasts [2] or on lymphoid line cells in
this study. Most likely, the G2M blocks observed in
our previous publication were due to active com-
pounds of ophthalmic medication and not due to
BAK’s influence, but studies on corneal epithelial cells
still need to be performed. BAK does not induce G2M
block enabling cell cycle progression and thus lym-
phocytes can proliferate and respond properly for
antigen stimulation. It should be state however that
Jurkat cells are neoplastic ones and they differ from
normal ones.
In conclusion, we want to state that BAK is rela-
tively toxic to lymphoid cells, especially causing ne-
crosis. In lower concentrations, it also shows moder-
ate apoptotic and minimal antiproliferative effect on
such cells. Other eye cells, especially superficial ones
such as corneal epithelial cells and conjunctival cells,
seem to be more resistant to BAK treatment. This
observation could suggest possible lymphoid dysfunc-
tion during intensive, prolonged topical BAK treat-
ment, even at a dosage relatively non-toxic to epithe-
lial eye cells.
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